

MADAME BIOSCIENCE

April 8, 2026

Subject : Invitation to the Annual General Meeting of Shareholders for the year 2026

To Shareholders of
Madame Bioscience Public Company Limited

Enclosure

1. Minutes of the Extraordinary General Meeting of Shareholders no. 1/2026
2. 56-1 one report, financial statements, and an auditor report for the year ending 31 December 2025 (QR Code)
3. Profile of candidates nominated in place of directors whose term has expired
4. Details of remuneration of directors for the year 2026
5. Details of auditors and auditing fees for the year 2026 (Compared to the year 2025)
6. Proxy Form A, Proxy Form B with the allonge, and Proxy C
7. Details of independent directors for proxy granting of The Annual General Meeting 2026
8. Articles of Regulation Rules for Shareholder Meeting
9. Rules for attending the shareholders' meeting via electronic media (E-AGM)
10. Acceptance of the invitation via electronic media form (E-AGM)
11. Procedure for submitting questions about the shareholders' meeting

The Board of Directors of Madame Bioscience Public Company Limited (the “**Company**”) has resolved to convene the Annual General Meeting of Shareholders for the year 2026 on April 23, 2026, at 2:00 p.m. (registration starts at 1:30 p.m.) by electronic meeting only (E-EGM) to consider the following agenda:

Agenda 1 To consider and certify the Minutes of the Extraordinary General Meeting of Shareholders No. 1/2026, which was held on January 27, 2026.

Rationale:

The Extraordinary General Meeting of Shareholders No. 1/2026, which was held on January 27, 2026. The minutes were submitted to the Stock Exchange of Thailand, the Securities and Exchange Commission, and the Ministry of Commerce as required by laws as well as posted on the company

MADAME BIOSCIENCE

website (<http://www.glocon.co.th>). A copy of the Minutes is attached to the shareholders in this invitation letter. Details are shown in Enclosure 1.

Board's opinion

The Board of Directors is of the opinion that the Minutes of the Extraordinary General Meeting of Shareholders No. 1/2026, which was held on January 27, 2026. were comprehensively and accurately recorded and recommended to be proposed to the Shareholders' Meeting for approval of the Annual General Meeting of Shareholders 2026.

Required votes

The majority votes of the shareholders who attend the meeting and cast their votes

Agenda 2 To acknowledge the Company's operating results for the year 2025.

Rationale:

The Company has summarized the operating results of the Company for the year 2025. It has appeared in 56-1 One Report, which is delivered in the form of a QR code to the shareholders to study the information together with the invitation letter. Details shown in Enclosure 2

Board's opinion

The Board of Directors, therefore, deemed it appropriate to propose to the Shareholders' Meeting to acknowledge the operational results of the preceding for the year 2025 and 56-1 One Report

Required votes

This agenda item was only for acknowledgment; there would be no voting.

Agenda 3 To consider and approve the consolidated and separate financial statements for the year 2025, ended December 31, 2025, along with the auditor's report.

MADAME BIOSCIENCE

Rationale:

The Statement of Financial Statement and Separate Financial Statement for the accounting period ended December 31, 2025, as set out in the Financial Statement that had been sent to the shareholders together with the 56-1 One Report of the year 2025. The Financial Statement was reviewed by the auditor, Deloitte Touche Tohmatsu Jaiyos Audit Company Limited, assessed and approved by the Audit Committee Meeting No. 1/2026, and approved by the Board of Directors meeting no. 2/2026.

Board's opinion

The Board of Directors, therefore, deemed it appropriate to propose to the Shareholders' Meeting to consider and approve the Consolidated Financial Statement and Separate Financial Statement which have been audited by the auditor for the accounting period ended December 31, 2025.

Required votes

The majority votes of the shareholders who attend the meeting and cast their votes.

Agenda 4 To consider and approve omission of dividend payment for the 2025 operating results.

Rationale:

The dividend payment must be approved by Shareholders' Meeting as set out in the Public Limited Companies Act, BE 2535 (1992) and the Company's Article of Association. The Company is able pay dividend only from its net profit. If the Company still has deficit, dividend payment is prohibited and the appropriation of net profit as legal reserve fund is not required.

According to the separate financial statement for the accounting period ended December 31, 2025, the Company has a net profit of 25.34 million baht and but has a total accumulated loss of 1,139.01 million baht. Therefore, the Company is unable to pay dividends for operating results of the year 2025 to shareholders which is in accordance with the limitation of the law.

MADAME BIOSCIENCE

Opinion of the Board:

The Board of Directors, therefore, deemed it appropriate to propose to the Shareholders' Meeting to consider and approve the dividend omission of the year 2025 due to the accumulated loss.

Required votes

The majority votes of the shareholders who attend the meeting and cast their votes.

- Agenda 5 To acknowledge the retirement of directors by rotation, and to consider and approve the re-election of the retiring directors for another term, and the election of new directors.**

Rationale:

In accordance with Clause 18 of the Company's Articles of Association stating that one-third of the total Directors must retire from office at every Annual General Meeting of shareholders. If the number of the total Directors is not multiple of three, then the number of Directors nearest to one-third must retire from office, whereby a Director who vacates office under this section may be re-elected.

At the Annual General Meeting of Shareholder 2026, there are three Directors who must retire by rotation, namely, (1) Miss Ingfa Petvipusit, (2) Mr.Tharakorn Junkerd and (3) Mr.Daniel Wu

Criteria for nomination and nominating method of directors

To consider the qualifications of the Company's director in accordance with the Public Limited Companies Act B.E. 2535, the educational background, skills, experience in the related business activities of the Company and the various professions which can support the business operation of the Company and contribute in developing the Company, including to the director's previous overall performance. As for the independent director, the Company has also considered the definition of the independent director set by the Securities and Exchange Commission, the Stock Exchange of Thailand, and by the Company together with consideration of any possible significant business relationship between the director and the Company which may cause the director to be unable to perform his/her duties independently.

The Nomination and Remuneration Committee has considered the qualifications of the Directors pursuant to the nomination procedures and deemed that three Directors namely, (1) Miss Ingfa

MADAME BIOSCIENCE

Petvipusit, (2) Mr.Tharakorn Junkerd and (3) Mr.Daniel Wu, are proficient and possess a various range of expertise. Therefore, they are deemed qualified for their positions. It is appropriate to propose that three Directors to be re-elected as Directors of the Company for another term. The details on education and experiences of the Director are presented in Enclosure 3.

The Company has provided the right for shareholders to nominate candidates for director's election in the Annual General Meeting 2026 from November 16, 2025 to January 31, 2026. After the specified period, no shareholder proposed any such matter at this Annual General Meeting of 2026.

Opinion of the Board:

The Board of Directors therefore agrees with the Nomination and Remuneration Committee and deemed it appropriate to propose to the Shareholders' Meeting to acknowledge the Directors who must retire by rotation namely, (1) Miss Ingfa Petvipusit, (2) Mr.Tharakorn Junkerd and (3) Mr.Daniel Wu and to consider appointing three directors namely, (1) Miss Ingfa Petvipusit, (2) Mr.Tharakorn Junkerd and (3) Mr.Daniel Wu to be the directors for another term.

Resolution:

This agenda item requires the approval of majority of the votes of the shareholders who attend the meeting and are entitled to vote by separating vote individually.

Agenda 6 To consider and approve the directors' remuneration for the year 2026.

Rationale:

According to Clause 36 of the Company's Articles of Association on the fixing of the remuneration of the directors stating that the fixing of director's remuneration shall be in accordance with a resolution passed by a Shareholders' Meeting, the Nomination and Remuneration Committee has considered the criteria to specify on remuneration payment to present to the Board of Directors meeting and in the Annual General Meeting for an approval respectively, as well as taken into suitability in various part of the rate of remuneration and compared it with the rate paid by other listed companies in the same industry, the potential business expansion and the profit growth of

MADAME BIOSCIENCE

the Company. It is appropriate to propose to the Shareholders' Meeting to consider and approve the Director's remuneration for the year 2026 at the amount of not exceeding 5,500,000 baht. The details of remuneration are presented in [Enclosure 4](#).

Opinion of the Board:

The Board of Directors, therefore, deemed it appropriate to propose to the Shareholders' Meeting to consider and approve the remuneration for Directors for the year 2026.

Required votes

No less than two-third of the shareholders who attend the meeting and cast their votes.

Agenda 7 To consider and approve the appointment of the Company's auditor and the determination of the audit fee for the year 2026.

Rationale:

The Company allows many audit companies to offer the audit fee for the year 2024 to the Audit Committee for consideration of qualifications and choose to be the auditor of the Company. The Audit Committee has considered the qualifications of each auditor and was of the view that Mr. Nopparoek Pissanuwong, Certified Public Accountant Registration No. 7764 and/or Ms. Raweevan Chuenchom, Certified Public Accountant Registration No. 7487 and/or Mrs. Suvimol Chiriyakierne, Certified Public Accountant Registration No. 2982 and/or Ms. Kamolmett Chiriyakierne, Certified Public Accountant No.10435 of DIA International Audit Company Limited by having one of the auditors to audit the accounts and express opinions on the financial statements of the Company and its subsidiaries and determine the remuneration for the year 2026 in total Baht 4,380,000 Baht, of which Baht 2,100,000 for the Company's remuneration and Baht 2,280,000 Baht for the subsidiaries' remuneration. The details of the remuneration are presented in [Enclosure 5](#).

Therefore, the auditors of DIA International Audit Company Limited have no relationship or interest in the Company, its subsidiaries, executives, major shareholders or interested persons.

Opinion of the Board:

The Board of Directors, therefore, deemed it appropriate to propose to the Shareholders' Meeting to consider and approve the appointment of Mr. Nopparoek Pissanuwong, Certified Public

MADAME BIOSCIENCE

Accountant Registration No. 7764 and/or Ms. Raweevan Chuenchom, Certified Public Accountant Registration No. 7487 and/or Mrs. Suvimol Chiriyakierne, Certified Public Accountant Registration No. 2982 and/or Ms. Kamolmett Chiriyakierne, Certified Public Accountant No.10435 of DIA International Audit Company Limited by having one of the auditors to audit the accounts and express opinions on the financial statements of the Company and its subsidiaries and determine the remuneration for the year 2026 in total Baht 4,380,000 Baht, of which Baht 2,100,000 for the Company's remuneration and Baht 2,280,000 Baht

Resolution:

This agenda item requires the approval of majority of the votes of the shareholders who attend the meeting and are entitled to vote.

Agenda 8 To consider and approve the reduction of the Company's registered capital and paid-up capital by reducing the par value of the Company's shares, and to consider and approve the amendment to Clause 4 of the Company's Memorandum of Association to reflect the reduction of the Company's registered capital.

Fact and Rationale

The Company intends to reduce the Company's registered capital by 2,018,198,852.88 Baht, from the existing registered capital of 3,003,272,102.50 Baht to the new registered capital of 985,073,249.62 Baht, and reduce the Company's paid-up capital by 1,357,118,852.88 Baht, from the existing paid-up capital of 2,019,522,102.50 Baht to 662,403,249.62 Baht, by reducing the par value of the Company's shares from 2.50 Baht per share to 0.82 Baht per share. The surplus arising from the reduction of paid-up capital, totaling 1,357,118,852.88 Baht, will be applied to offset the share discount of 225,601,093.00 Baht and the Company's accumulated losses of 1,131,517,759.88 Baht. The total number of ordinary shares shall remain unchanged at 807,808,841 shares. Following the completion of such capital reduction, the Company will have remaining accumulated losses of 7,493,120.12 Baht.

The aforementioned capital reduction shall not have any impact on the total shareholders' equity of the Company. The Company's shareholders' equity shall remain unchanged in all respects, and the intrinsic value of the Company's shares shall remain unaffected. The capital reduction is affected solely as an accounting adjustment, the details of which are as follows:

MADAME BIOSCIENCE

(Unit: Baht)	Separate Financial Statement as of 31 December 2025		
	<u>Before the change of</u> par value of shares	Change	<u>After the change of</u> par value of shares
Par Value	2.50	(1.68)	0.82
Registered capital	3,003,272,102.50	(2,018,198,852.88)	985,073,249.62
Paid-up capital	2,019,522,102.50	(1,357,118,852.88)	662,403,249.62
Share Discount	(225,601,093.00)	225,601,093.00	-
Convertible debentures - equity component	39,679,064.00	-	39,679,064.00
Deficits	(1,139,010,880.00)	1,131,517,759.88	(7,493,120.12)
Other components of shareholders' equity	23,536,000.00	-	23,536,000.00
Total shareholders' equity	718,125,193.50	-	718,125,193.50

Remark:

- The above table presents a simulation of the Company's shareholders' equity following the reduction of the registered capital and paid-up capital, based on the separate financial statements as of 31 December 2025. However, subsequent to 31 December 2025, the Company undertook a capital restructuring in accordance with the resolution of the Extraordinary General Meeting of Shareholders No. 1/2026, held on 28 January 2026, which approved (1) a reduction of the registered capital by 15,000,000.00 Baht, (2) an increase of the registered capital by 1.00 Baht, and (3) a change in the par value of the shares by way of a share consolidation, from the original par value of 0.50 Baht per share to 2.50 Baht per share. As the financial statements as of 31 December 2025 do not yet reflect the effects of such resolutions, the Company has prepared pro forma financial statements by adjusting the accounting figures to reflect the changes in capital structure in accordance with the aforesaid shareholders' resolution.

In this regard, the reduction of the Company's registered capital and paid-up capital as mentioned above does not reduce the capital to less than one-fourth of the total capital, in compliance with Section 139 of the Public Limited Companies Act B.E. 2535, as amended (the "Public Limited Companies Act"). Upon obtaining approval from the shareholders' meeting, the Company shall notify the Company's creditors of the resolution to reduce the capital within fourteen (14) days from the date of the shareholders' meeting resolution, and shall specify a period for creditors to submit any objections within two (2) months from the date of receipt of such notice. In addition, the Company shall publish the resolution in a newspaper or on the Company's website at

MADAME BIOSCIENCE

<http://www.glocon.co.th> within fourteen (14) days from the date of the shareholders' meeting resolution, in accordance with Section 141 of the Public Limited Companies Act B.E. 2535, as amended.

In this regard, the Executive Committee, or any person(s) designated by the Executive Committee, is hereby authorized to consider and determine any other details relating to the reduction of the registered capital and paid-up capital, including but not limited to the following:

- (1) The determination of the terms, conditions, and other details relating to the reduction of the registered capital and paid-up capital by reducing the par value of the shares.
- (2) To negotiate, enter into, and execute any applications and related documents in connection with the reduction of the registered capital and paid-up capital by reducing the par value of the shares, including the submission of any applications, documents, and evidence to any governmental authority or relevant agency, and to take any other actions as may be necessary and appropriate in relation to the aforesaid capital reduction, as deemed appropriate, in compliance with applicable laws and/or regulations.

Accordingly, upon completion of the aforementioned capital restructuring process, the Company's registered capital and total number of shares shall be as follows:

Details	Amount
Registered capital	985,073,249.62 Baht
Paid-up capital	662,403,249.62 Baht
Par value (per share)	0.82 Baht

In addition, to comply with the law, it is resolved to propose to the shareholders' meeting to consider and approve the amendment to Clause 4 of the Company's Memorandum of Association to be in line with the reduction of the Company's registered capital as follows:

MADAME BIOSCIENCE

“Clause 4.	Registered Capital	985,073,249.62 Baht	(Nine Hundred Eighty-Five Million Seventy-Three Thousand Two Hundred Forty-Nine Baht and Sixty- Two Satang)
	Equivalent to:	1,201,308,841 Shares	(One Billion Two Hundred One Million Three Hundred Eight Thousand Eight Hundred Forty-One shares)
	Par value:	0.82 Baht	(Eighty-Two Satang)
	Divided into:		
	Ordinary share:	1,201,308,841 Shares	(One Billion Two Hundred One Million Three Hundred Eight Thousand Eight Hundred Forty-One shares)
	Preferred share:	- Shares	(-)”

Including the authorization of the Company’s authorized director(s) and/or any person(s) appointed by such authorized director(s) to determine the terms and details relating to the implementation of the aforesaid capital reduction, as well as to amend any wording or statements in the minutes of the shareholders’ meeting, the Memorandum of Association, and/or any applications and related documents, and/or to undertake any acts necessary to comply with the registrar’s orders in connection with the registration of the capital reduction and the amendment to the Company’s Memorandum of Association with the Department of Business Development, Ministry of Commerce.

The procedures and implementation timeline are set out as follows:

Item	Process	Date	Remark
1.	The Annual General Meeting of Shareholders for the Year 2026	April 23, 2026	Meeting held within 2 months from the Record Date, which is set for March 13, 2026
2.	Register the capital reduction resolution with the Department of Business Development, Ministry of Commerce	The last week of April 2026 to the first week of May 2026	Within 14 days from the date of the resolution of the Annual General Meeting of

MADAME BIOSCIENCE

Item	Process	Date	Remark
3.	Notify the Company's creditors of the capital reduction resolution and publish the resolution in a newspaper or on the Company's website		Shareholders for the Year 2026
4.	Objection Submission Deadline for Creditors	The last week of June 2026 to the first week of July 2026	After the lapse of 2 months from the date the creditor receives the notice of the capital reduction resolution (as per item 3)
5.	Registration of the reduction of registered capital and paid-up capital (through <u>reduction of the par value</u> of the Company's shares) and the amendment to the Memorandum of Association with the Department of Business Development, Ministry of Commerce	The second week of July 2026 to the third week of July 2026	Within 14 days from the expiry of the creditor objection period (2 months) (as per item 4), provided that no creditor has raised any objection, or in the event that an objection has been raised, the Company has settled the debt or provided security for such debt

Remark: The above schedule is subject to change.

Opinion of the Board of Directors

The Board of Directors, having considered the matter, is of the opinion that it should be proposed to the shareholders' meeting for consideration and approval of the reduction of the Company's registered capital and paid-up capital by reducing the par value of the Company's shares, and to consider and approve the amendment to Clause 4 of the Company's Memorandum of Association to reflect the reduction of the Company's registered capital. This includes the granting of relevant authorities as proposed to facilitate any necessary and appropriate actions in connection with the reduction of the Company's registered capital and paid-up capital by reducing the par value of the Company's shares, and the amendment to the Company's Memorandum of Association with

MADAME BIOSCIENCE

the Department of Business Development, Ministry of Commerce, in order to ensure the orderly implementation thereof.

Resolution

Resolution of this Agenda shall be approved by not less than three quarter (3/4) of the shareholders attending the meeting and having the right to vote.

Agenda 9 To consider other matters (if any).

As a result, the Board of Directors has determined the Record Date for the Annual General Meeting of Shareholders of the year 2026 on March 13, 2026.

Therefore, please be invited to attend the Annual General Meeting of Shareholders of the year 2026, which will be arranged as E-Meeting on the aforementioned date and time and in order to facilitate the registration to attend the shareholders' meeting as E-Meeting, the Company would like to request that the shareholders follow the practical guidance for E-Meeting Enclosure 9.

In the event any shareholder who cannot personally attend the shareholders' meeting, such shareholder can grant proxy to other or to independent director, whose names are listed in the Names of Independent Directors acting as proxy for the Annual General Meeting of Shareholders of the year 2026, Enclosure 7, by completing and executing the Proxy Form A, Form B and Form C for E-Meeting, Enclosure 6, which can be downloaded from the Company's website (<http://www.glocon.co.th>), and please only use either one of these forms.

Sincerely yours,



(Mr.Tharakorn Junkerd and Miss Ingfa Petvipusit)

Authorized Director

MADAME BIOSCIENCE

Remark:

1. For your convenience, it is kindly requested that the shareholders and/or the proxies do pre-registration in advance between 20 April 2026 and 22 April 2026. Please comply with the Enclosure 10.
2. The shareholders can download the invitation letter for the Annual General Meeting of Shareholders 2026 and the accompanying documents from website www.glocon.co.th from April 8, 2026 onwards.
3. To facilitate the registration process, shareholders can send the completed proxy form in advance to the following address: OJ International Company Limited., 5/6 Tessaban Rangsarit Nuea Road, Lat Yao, Chatuchak, Bangkok 10900

Attn: Registrar of Public Company Limited
Department Stock Exchange of Thailand
The Securities and Exchange Commission

MADAME BIOSCIENCE

Enclosure 1

Minutes of Extraordinary General Meeting of Shareholders No. 1/2026

Madame Bioscience Public Company Limited

60 Soi Pradit Manutham 19, Pradit Manutham Road, Lat Phrao Sub-district, Lat Phrao District, Bangkok
10230 (E-Meeting)

Time and Location

The Extraordinary General Meeting of Shareholders No. 1/2026 of Madame Bioscience Public Company Limited was held on 28 January 2026 at 2:00 PM.

The Company held the meeting at the main conference room located at 60 Soi Pradit Manutham 19, Pradit Manutham Road, Lat Phrao Sub-district, Lat Phrao District, Bangkok 10230, in an electronic meeting format (E-Meeting).

Presented Directors and Executives (Onsite)

- | | | |
|----|---------------------------|---|
| 1. | Mr. Chumpol Rimsakorn | Chairman |
| 2. | Mr. Anant Sirisaengtaksin | Audit Committee Chairman and Independent Director |
| 3. | Miss Chularat Suteethorn | Audit Committee Member and Independent Director |
| 4. | Miss Ingfa Petvipusit | Director, Executive Director and Acting Chief Executive Officer |
| 5. | Mr. Tharakorn Junkerd | Director |
| 6. | Mr. Praween Deekajonedej | Executive Director and Chief Financial Officer |

Presented Directors via Electronic Means (Online)

- | | | |
|----|-------------------------|-------------------------------------|
| 1. | Ms. Rossiri Rattanaprue | Director and Audit Committee Member |
| 2. | Mr. Akarat Vannarat | Director |

Meeting Commencement

The Master of Ceremony informed the meeting that today is the Extraordinary General Meeting of Shareholders No. 3/2025, with Mr. Chumpol Rimsakorn, Chairman of the Board, acting as the Chairman of the meeting (the “Chairman”). At present, there are 33 shareholders attending the meeting in person and by proxy, holding an aggregate of 1,920,543,460 shares, representing 47.5495 percent of the total issued shares of the

14

MADAME BIOSCIENCE

Company, being 4,039,044,203 shares in total. This constitutes a quorum in accordance with the Public Companies Limited Act B.E. 2535 (1992) and the Company's Articles of Association. Therefore, the Chairman was invited to declare the meeting open.

The Chairman declared the meeting open and assigned the Master of Ceremony to explain the procedures for casting votes and counting the votes to the meeting.

The Master of Ceremony then explained to the meeting the procedures for casting votes, counting the votes, as well as the procedures for inquiries and expressing opinions of the shareholders for each agenda item.

- to be input -

The Chairman then proceeded with the meeting in accordance with the agenda as follows:

Agenda 1 To consider and approve the minutes of the Extraordinary General Meeting of Shareholders No. 3/2025 held on September 19, 2025

Consideration and approval of the Minutes of the Extraordinary General Meeting of Shareholders No. 3/2025, held on 19 September 2025

The Company has duly prepared the Minutes of the Extraordinary General Meeting of Shareholders No. 3/2025, held on 19 September 2025, accurately and completely. Copies of the said minutes have been submitted to the Stock Exchange of Thailand and the Department of Business Development, Ministry of Commerce, in accordance with applicable laws, and have also been published on the Company's website (<http://www.glocon.co.th>). Details of the minutes are set out in Enclosure 1.

For this agenda item, the Board of Directors has considered and is of the opinion that the Minutes of the Extraordinary General Meeting of Shareholders No. 3/2025, held on 19 September 2025, were properly and completely recorded. Accordingly, it is deemed appropriate to propose that the shareholders' meeting consider and approve the said minutes.

The resolution for this agenda item shall require approval by a majority vote of the shareholders present at the meeting and entitled to vote.

MADAME BIOSCIENCE

The Chairman invited the meeting to raise questions and express opinions. As no shareholder raised any questions or comments, the Chairman therefore proposed that the meeting consider approving the Minutes of the Extraordinary General Meeting of Shareholders No. 3/2025, held on 19 September 2025.

Resolution The meeting duly considered and resolved to approve the Minutes of the Extraordinary General Meeting of Shareholders No. 3/2568, held on 19 September 2568, by unanimous vote of the total votes of the shareholders present at the meeting and entitled to vote, as follows:

Approved:	1,920,543,460	votes	Equivalent to	100 percent
Disapproved:	0	votes	Equivalent to	0 percent
Abstained:	0	votes	Equivalent to	0 percent
Voided:	0	votes	Equivalent to	0 percent

from the total voting right of 1,920,543,460 of the shareholders who attend the meeting and casting their vote.

Agenda 2 To consider and approve the reduction of the Company's registered capital by canceling the unissued shares, and to consider and approve the amendment to Clause 4 of the Company's Memorandum of Association to be in line with the reduction of the Company's registered capital.

The Master of Ceremony informed the meeting that the Company intends to reduce its registered capital by THB 15,000,000.00, from the existing registered capital of THB 3,018,272,101.50, divided into 6,036,544,203 ordinary shares with a par value of THB 0.50 per share, to a new registered capital of THB 3,003,272,101.50, divided into 6,006,544,203 ordinary shares with a par value of THB 0.50 per share. This will be achieved by cancelling 30,000,000 unissued ordinary shares with a par value of THB 0.50 per share, which were originally reserved for the exercise of convertible debentures No. 1/2025 (which the Company fully redeemed prior to maturity on 4 December 2025).

In addition, in order to comply with applicable laws, it is proposed to submit to the shareholders' meeting for consideration and approval the amendment of Clause 4 of the Company's Memorandum of Association to reflect the reduction of the Company's registered capital, as follows:

MADAME BIOSCIENCE

Clause 4.	Registered Capital	3,003,272,101.50 Baht	(Three Billion Three Million Two Hundred Seventy-Two Thousand One Hundred and One Baht and Fifty Satang)
	Equivalent to:	6,006,544,203 Shares	(Six Billion Six Million Five Hundred Forty-Four Thousand Two Hundred and Three Shares)
	Par value:	0.50 Baht	(Fifty Satang)
	Divided into:		
	Ordinary share:	6,006,544,203 Shares	(Six Billion Six Million Five Hundred Forty-Four Thousand Two Hundred and Three Shares)
	Preferred share:	- Shares	(-)

For this agenda item, the Board of Directors has considered and deemed it appropriate to propose to the shareholders' meeting for consideration and approval the reduction of the Company's registered capital from unissued shares, as well as the amendment of Clause 4 of the Company's Memorandum of Association to reflect such reduction. In order to facilitate any necessary and appropriate actions relating to the registered capital reduction, including the registration of the capital reduction and the amendment of the Company's Memorandum of Association with the Department of Business Development, Ministry of Commerce, the related authorizations shall be granted in all respects as proposed above.

The resolution for this agenda item shall require approval by not less than three-fourths (3/4) of the total votes of the shareholders present at the meeting and entitled to vote.

The Chairman invited the meeting to raise questions and express opinions. As no shareholder raised any questions or expressed further opinions, the Chairman therefore proposed that the meeting consider and resolve to approve the reduction of the Company's registered capital from unissued shares and the amendment of Clause 4 of the Company's Memorandum of Association to reflect such reduction, as proposed.

MADAME BIOSCIENCE

Resolution: The meeting duly considered and resolved to approve the reduction of the Company's registered capital from unissued shares and the amendment of Clause 4 of the Company's Memorandum of Association to reflect such reduction, by a vote of not less than three-fourths (3/4) of the total votes of the shareholders present at the meeting and entitled to vote, as follows:

Approved:	1,920,543,460	votes	Equivalent to	100 percent
Disapproved:	0	votes	Equivalent to	0 percent
Abstained:	0	votes	Equivalent to	0 percent
Voided:	0	votes	Equivalent to	0 percent

from the total voting right of 1,920,543,460 of the shareholders who attend the meeting and casting their vote.

Agenda 3 To consider and approve the increase of the Company's registered capital, and to consider and approve the amendment of Clause 4 of the Company's Memorandum of Association to reflect such increase in the Company's registered capital.

The Master of Ceremony informed the meeting that the Company intends to increase its registered capital by THB 1.00, from the existing registered capital of THB 3,003,272,101.50, divided into 6,006,544,203 ordinary shares with a par value of THB 0.50 per share, to a new registered capital of THB 3,003,272,102.50, divided into 6,006,544,205 ordinary shares with a par value of THB 0.50 per share. This will be achieved through the issuance of 2 newly issued ordinary shares with a par value of THB 0.50 per share, to support the issuance and offering of newly issued ordinary shares to specific investors under a Private Placement (PP).

In addition, to comply with the law, it is resolved to propose to the shareholders' meeting to consider and approve the amendment to Clause 4 of the Company's Memorandum of Association to be in line with the increase of the Company's registered capital as follows:

Clause 4.	Registered Capital	3,003,272,102.50	(Three Billion Three Million Two Hundred Seventy-Two Thousand One Hundred and Two Baht and Fifty Satang)
-----------	--------------------	------------------	---

MADAME BIOSCIENCE

Equivalent to:	6,006,544,205 Shares	(Six Billion Six Million Five Hundred Forty-Four Thousand Two Hundred and Five Shares)
Par value:	0.50 Baht	(Fifty Satang)
Divided into:		
Ordinary share:	6,006,544,205 Shares	(Six Billion Six Million Five Hundred Forty-Four Thousand Two Hundred and Five Shares)
Preferred share:	- Shares	(-)

Including the authorization of the Company's authorized directors and/or any person designated by the Company's authorized directors to determine the conditions and details relating to the aforementioned capital increase, as well as to amend wording or statements in the minutes of the shareholders' meeting, the Memorandum of Association, and/or any applications, and/or to undertake any actions necessary to comply with the registrar's instructions for the registration of the capital increase and the amendment to the Company's Memorandum of Association with the Department of Business Development, Ministry of Commerce.

For this agenda item, the Board of Directors has considered and deemed it appropriate to propose to the shareholders' meeting for consideration and approval the increase of the Company's registered capital, as well as the amendment of Clause 4 of the Company's Memorandum of Association to reflect such increase. In order to facilitate any necessary and appropriate actions relating to the registered capital increase, including the registration of the capital increase and the amendment of the Company's Memorandum of Association with the Department of Business Development, Ministry of Commerce, the related authorizations shall be granted in all respects as proposed above.

The resolution for this agenda item shall require approval by not less than three-fourths (3/4) of the total votes of the shareholders present at the meeting and entitled to vote.

As Agenda Items 3, 4, and 5 are interrelated and conditional upon one another, if any one of these agenda items is not approved by the Extraordinary General Meeting of Shareholders No. 1/2569, the remaining related and conditional agenda items shall not be considered, and any related and conditional agenda items previously approved shall be deemed cancelled.

MADAME BIOSCIENCE

The Chairman invited the meeting to raise questions and express opinions. As no shareholder raised any questions or further comments, the Chairman therefore proposed that the meeting consider and approve the increase of the Company's registered capital, the amendment of Clause 4 of the Company's Memorandum of Association to reflect such increase, and the related authorizations in all respects as

Resolution: The meeting duly considered and resolved to approve the increase of the Company's registered capital, the amendment of Clause 4 of the Company's Memorandum of Association to reflect such increase in the registered capital, and the granting of the related authorizations in all respects as proposed above, by a vote of not less than three-fourths (3/4) of the total votes of the shareholders present at the meeting and entitled to vote, as follows:

Approved:	1,920,543,460	votes	Equivalent to	100 percent
Disapproved:	0	votes	Equivalent to	0 percent
Abstained:	0	votes	Equivalent to	0 percent
Voided:	0	votes	Equivalent to	0 percent

from the total voting right of 1,920,543,460 of the shareholders who attend the meeting and casting their vote.

Agenda 4 To consider and approve the allocation of the Company's newly issued ordinary shares to be offered to specific investors (Private Placement: PP).

The Master of Ceremony informed the meeting that the Company intends to allocate newly issued ordinary shares, whether in a single offering or multiple offerings, in a total amount not exceeding 2 shares, with a par value of THB 0.50 per share, by way of a Private Placement (PP) to a specific investor, namely Ms. Chanita Sueabkaew ("the Investor"). The Investor is not a connected person of the Company pursuant to the Notification of the Capital Market Supervisory Board No. TorJor. 21/2008 Re: Rules on Connected Transactions and the Notification of the Stock Exchange of Thailand Re: Disclosure of Information and Other Acts of Listed Companies Concerning Connected Transactions B.E. 2546 (2003) (collectively, the "Connected Transaction Notifications").

MADAME BIOSCIENCE

The issuance of such newly issued ordinary shares represents an offering for which the Board of Directors has resolved to propose to the shareholders' meeting to determine the offering price clearly at THB 0.50 per share (at par value), which is not lower than 90% of the market price. Following the capital increase through this private placement, the Company will receive total proceeds of THB 1.00, and the Investor will hold not more than 2 shares, representing approximately 0.00% of the total issued and paid-up shares, in accordance with the Notification of the Capital Market Supervisory Board No. TorJor. 28/2022 Re: Approval for Listed Companies to Offer Newly Issued Shares by Way of Private Placement dated 28 December 2022 (as amended) ("TorJor. 28/2022 Notification").

In addition, as the Company has accumulated losses as shown in the audited separate financial statements for the year ended 31 December 2024 and the reviewed separate financial statements for the period ended 30 September 2025, the Company may determine an offering price below the par value, provided that such price is not lower than THB 0.01 per share, subject to compliance with Section 52 of the Public Limited Companies Act. Nevertheless, the Company has determined the offering price at THB 0.50 per share, which is higher than the market price.

The market price has been calculated based on the weighted average price of the Company's shares traded on the Stock Exchange of Thailand ("SET") over the 15 consecutive business days prior to the date on which the Board of Directors resolved to propose this agenda to the shareholders' meeting, being from 2 December 2025 to 24 December 2025, at THB 0.14 per share (source: SET).

Pursuant to the TorJor. 28/2022 Notification, the Company must complete the share offering within the period approved by the shareholders' meeting, which must not exceed 3 months from the date of shareholders' approval, or within 12 months if the shareholders' meeting clearly resolves to authorize the Board of Directors to determine the offering price based on the market price at the time of offering after such 3-month period.

The Investor has no related persons holding shares of the Company, meaning there are no concert parties, no persons under Section 258 of the Securities and Exchange Act B.E. 2535 (1992) (as amended), and no nominees whose shareholdings must be aggregated. Accordingly, the Investor will not be required to make a mandatory tender offer, as the shareholding resulting from this transaction will not reach 25% of the total voting rights of the Company under the Notification of the Capital Market Supervisory Board No. TorJor. 12/2011

MADAME BIOSCIENCE

Re: Rules, Conditions and Procedures for the Acquisition of Securities for Business Takeovers dated 13 May 2011 (as amended).

In addition, it is proposed to authorize the Board of Directors and/or the Executive Chairman and/or the Chief Executive Officer and/or the authorized directors of the Company and/or any person designated by such authorized persons to undertake any actions relating to the issuance, offering, allocation, and subscription of the newly issued ordinary shares, including but not limited to:

1. Determining and/or amending any necessary details relating to the allocation of the newly issued ordinary shares, provided that such actions do not conflict with applicable laws, regulations, or notifications, including determination or amendment of subscription dates, offering periods, payment terms, and whether the allocation will be conducted in a single or multiple tranches.
2. Contacting, negotiating, executing, signing, amending agreements, applications, waivers, notices, and any relevant documents relating to the allocation of such newly issued shares, including share subscription agreements, registration with the Ministry of Commerce, submission of applications or documentation to the SEC, the SET, and relevant governmental authorities, as well as listing the newly issued shares on the SET.
3. Undertaking any necessary actions to ensure the successful completion of the allocation of such newly issued ordinary shares, including the appointment or delegation of authority to appropriate persons.

Details of the issuance and offering of newly issued ordinary shares by way of Private Placement are set out in the Capital Increase Report Form (F53-4) (Enclosure 2) and the Information Memorandum regarding the issuance and offering of newly issued ordinary shares by way of Private Placement of Madame Bioscience Public Company Limited (Enclosure 3).

For this agenda item, the Board of Directors has considered and deemed it appropriate to propose to the shareholders' meeting for consideration and approval the allocation of newly issued ordinary shares of the Company to specific investors by way of a Private Placement (PP), together with the granting of all related authorizations in all respects as proposed above.

The resolution for this agenda item shall require approval by a majority vote of the shareholders present at the meeting and casting their votes.

MADAME BIOSCIENCE

As Agenda Items 3, 4, and 5 are interrelated and conditional upon one another, if any one of these agenda items is not approved by the Extraordinary General Meeting of Shareholders No. 1/2026, the remaining related and conditional agenda items shall not be considered, and any previously approved related and conditional agenda items shall be deemed cancelled.

The Chairman invited the meeting to raise questions and express opinions. As no shareholder raised any questions or further comments, the Chairman therefore proposed that the meeting consider and approve the allocation of newly issued ordinary shares to specific investors by way of Private Placement (PP), together with the related authorizations in all respects as proposed above.

Resolution The meeting duly considered and resolved to approve the allocation of the Company's newly issued ordinary shares to specific investors by way of a Private Placement (PP), together with the granting of all related authorizations in all respects as proposed above, by a majority vote of the total votes of the shareholders present at the meeting and entitled to vote, as follows:

Approved:	1,920,543,460	votes	Equivalent to	100 percent
Disapproved:	0	votes	Equivalent to	0 percent
Abstained:	0	votes	Equivalent to	0 percent
Voided:	0	votes	Equivalent to	0 percent

from the total voting right of 1,920,543,460 of the shareholders who attend the meeting and casting their vote.

Agenda 5 To consider and approve the change in the par value of the Company's shares through share consolidation, and to consider and approve the amendment of Clause 4 of the Company's Memorandum of Association to reflect such change in par value.

The Master of Ceremony informed the meeting that the Company intends to change the par value of its shares through share consolidation, from the existing par value of THB 0.50 per share to THB 2.50 per share. As a result, the total number of the Company's shares will be reduced by 4,805,235,364 shares, from 6,006,544,205 shares with a par value of THB 0.50 per share to 1,201,308,841 shares with a par value of THB

MADAME BIOSCIENCE

2.50 per share. Such change in par value will result in a reduction in the number of shares held by each shareholder at a ratio of 5 existing ordinary shares to 1 new ordinary share, as follows:

	<u>Before</u> the change of par value of shares	<u>After</u> the change of par value of shares
Registered capital*	3,003,272,102.50 Baht	3,003,272,102.50 Baht
Paid-up capital	2,019,522,102.50 Baht	2,019,522,102.50 Baht
Number of registered shares*	6,006,544,205 Shares	1,201,308,841 Shares
Number of paid-up shares	4,039,044,205 Shares	807,808,841 Shares
Par value of shares	0.50 Baht / Shares	2.50 aht / Shares

For the purpose of changing the par value of the shares from THB 0.50 per share to THB 2.50 per share, the calculation may result in certain shareholders holding fractional shares insufficient to be converted into new shares. Any such fractional shares arising from the calculation shall be rounded down. The Company will appoint Thailand Securities Depository Company Limited (“TSD”), the Company’s share registrar, to perform the calculation of the par value change and the rounding of fractional shares in accordance with TSD’s operational procedures.

In this regard, to protect the rights of shareholders affected by such fractional shares, shareholders may buy or sell odd lots on the Stock Exchange of Thailand (“SET”) in order to obtain sufficient shares for the share consolidation prior to the effective date of the change in par value. However, for shareholders whose remaining fractional shares are insufficient to be converted into new shares and are consequently rounded down, the Company will provide cash compensation for such fractional shares at THB 0.50 per share (being equal to the Company’s original par value). Each affected shareholder may request compensation for fractional shares through the following methods:

- (1.) To receive cash compensation for fractional shares in person at the Company’s office located at No. 60, 2nd Floor, Soi Praditmanutham 19, Praditmanutham Road, Ladprao Subdistrict, Ladprao District, Bangkok 10230; or
- (2.) To notify the Company in writing of the intention to receive compensation for fractional shares by bank transfer, either by postal mail addressed to the Company or by electronic mail (E-mail) to

MADAME BIOSCIENCE

preween@glocon.co.th or legal@glocon.th, together with valid identification documents of the shareholder (e.g., copy of national ID card, government officer card, state enterprise employee card, passport, or certificate of juristic person, as applicable), and a copy of the bank account intended to receive the transfer, whereby the account holder's name must correspond with the shareholder's name. The Company shall proceed with the transfer of compensation upon verification of the submitted information.

In this regard, shareholders must request cash compensation in person or notify their intention to receive compensation by bank transfer within one (1) month from the date on which the registration of the change in par value of the Company's shares has been completed with the Department of Business Development, Ministry of Commerce, which is expected to occur in February 2026. The Company will further announce the details through the SET disclosure system. Should any shareholder fail to claim the cash compensation or notify the intention to receive compensation by bank transfer within the specified period, such shareholder shall be deemed to have waived the right to receive the said compensation.

In addition, it is proposed to authorize the Executive Committee, or any person designated by the Executive Committee, to undertake any actions necessary and appropriate in connection with the change in par value of the shares through share consolidation in all respects, including but not limited to determining the terms and conditions relating to the payment of compensation for fractional shares, and making any notifications or obtaining approvals from relevant authorities to ensure compliance with applicable laws and regulations.

Furthermore, in order to comply with applicable laws, it is proposed to submit to the shareholders' meeting for consideration and approval the amendment of Clause 4 of the Company's Memorandum of Association to reflect the change in the par value of the Company's shares, by replacing the wording as follows:

Clause 4. Registered capital 3,003,272,102.50 Baht (Three Billion Three Million Two
Hundred Seventy-Two Thousand

MADAME BIOSCIENCE

		One Hundred and Two Baht and Fifty Satang)
Divided into	1,201,308,841 Shares	(One Billion Two Hundred One Million Three Hundred Eight Thousand Eight Hundred Forty-One Shares)
Par value per share	2.50 Baht	(Two Baht and Fifty Satang)
Divided into:		
Ordinary share	1,201,308,841 Shares	(One Billion Two Hundred One Million Three Hundred Eight Thousand Eight Hundred Forty-One Shares)
Preferred share	- Shares	(-)"

Including the authorization granted to the Company's authorized directors and/or any person designated by such authorized directors to determine the terms and conditions and details relating to the implementation of the change in par value of the shares, as well as to amend any wording or statements in the minutes of shareholders' meetings, the Company's Memorandum of Association, and/or any related applications or documents, and/or to undertake any actions necessary to comply with the registrar's orders in connection with the registration of the change in par value of the shares and the amendment of the Company's Memorandum of Association with the Department of Business Development, Ministry of Commerce.

In addition, in connection with the aforementioned change in the par value of the Company's shares, the Company will be required to adjust the exercise price and the exercise ratio of the Warrants to Purchase Ordinary Shares of the Company No. 6 (MADAME-W6) in accordance with the terms and conditions governing the rights and obligations of the issuer and holders of the Warrants to Purchase Ordinary Shares of Madame Bioscience Public Company Limited No. 6 (MADAME-W6) ("MADAME-W6 Terms and Conditions"), in order to preserve the rights and benefits of the warrant holders. The details and calculation formula are as follows:

MADAME BIOSCIENCE

	Before Rights Adjustment Par value 0.50 Baht per share	After Rights Adjustment Par value 2.50 Baht per share
Exercise Price	0.25 Baht per share	1.25 Baht per share
Exercise Ratio	1 warrant unit per 1 ordinary share of the Company	1 warrant unit per 0.20 ordinary share of the Company

The implementation procedures and timeline shall be as follows:

No.	Process	Date	Remark
1.	Extraordinary General Meeting of Shareholders No. 1/2026	January 28, 2026	Meeting held within 2 months from the Record Date, which is set for January 9, 2026
2.	Registering capital reduction and increase and the amendment to the Memorandum of Association with the Department of Business Development, Ministry of Commerce	Last week of January 2026 to 1st week of February 2026	Within 14 days from the date the Extraordinary General Meeting of Shareholders No. 1/2026 passes its resolution for approval
3.	Registration of the change in par value of the Company's shares (by means of a <u>reverse stock-split</u>) and amendment to the Memorandum of Association with the Department of Business Development, Ministry of Commerce		
4.	Due date for receiving cash compensation for fractional shares from the change in par value	Last week of January 2026 to Last week of February 2026	Within 1 month from the date of registration of the change in par value (as per item 3) with the Department of Business

MADAME BIOSCIENCE

No.	Process	Date	Remark
			Development, Ministry of Commerce

For this agenda item, the Board of Directors considered and resolved that it is appropriate to propose to the shareholders' meeting for consideration and approval the change in the par value of the Company's shares by way of share consolidation, together with the amendment to Clause 4 of the Company's Memorandum of Association to be consistent with such change in par value. This includes the authorization for any acts necessary and appropriate in connection with the implementation of the share consolidation, including but not limited to the registration of the change in par value and the amendment to the Memorandum of Association with the Department of Business Development, Ministry of Commerce, as well as the granting of related authorizations as proposed.

The resolution for this agenda item requires an approval vote of not less than three-fourths (3/4) of the total votes of shareholders attending the meeting and having voting rights.

Since Agenda Items 3, 4, and 5 are interrelated and conditional upon one another, if any of such agenda items is not approved by the Extraordinary General Meeting of Shareholders No. 1/2026, the remaining related agenda items shall not be considered, and any previously approved related agenda items shall be deemed cancelled.

The Chairman invited shareholders to raise questions and express their opinions.

Mr. Apichart Asawatevawich, a shareholder attending the meeting in person, inquired whether the Company has any future plan to reduce the par value of shares in order to eliminate accumulated losses, and the expected timeline for such action.

Mr. Praveen Deekajorndech clarified that the Company is currently considering the feasibility and appropriateness of such par value reduction. Should there be any material development, the Company will duly inform shareholders accordingly.

MADAME BIOSCIENCE

As no further questions or comments were raised, the Chairman proposed that the meeting consider and approve the change in the par value of shares by way of share consolidation, the amendment to Clause 4 of the Memorandum of Association, and the granting of related authorizations as proposed in all respects.

Resolution: The meeting considered and resolved to approve the change in the par value of the Company's shares by way of share consolidation, including the amendment to Clause 4 of the Memorandum of Association of the Company to reflect such change, as well as the related authorizations as proposed in all respects, with a vote of not less than three-fourths (3/4) of the total voting rights of the shareholders present at the meeting and entitled to vote, as follows:

Approved:	1,920,543,460	votes	Equivalent to	100 percent
Disapproved:	0	votes	Equivalent to	0 percent
Abstained:	0	votes	Equivalent to	0 percent
Voided:	0	votes	Equivalent to	0 percent

from the total voting right of 1,920,543,460 of the shareholders who attend the meeting and casting their vote.

Agenda 6 To consider other matters (if any).

The Chairman invited the meeting to raise questions and express opinions on other matters.

Mr. Apichart Asavatevavich, a shareholder attending the meeting in person, inquired that, following the disposal of the Packaging and Fruity Dry businesses, the MADAME LOUISE business should become the Company's core business. He therefore requested the management to present its vision on how the MADAME LOUISE business will achieve growth over the next two years in terms of generating sales and profitability.

Mr. Praween Deekajordej responded that the MADAME LOUISE business is currently expanding beyond domestic distribution, with products already being introduced into overseas markets such as China, India, and Vietnam. In addition, the Company continues to develop new products to be launched in the market to increase sales. These new products are not limited to beauty products alone, as the Company has also begun expanding into dietary supplement products.

MADAME BIOSCIENCE

The Chairman informed the meeting that, as no further matters were proposed by any shareholder, he would like to thank all shareholders and proxies for taking the time to attend the meeting today. He also expressed his apologies to the shareholders for any shortcomings or inconveniences that may have occurred.

The meeting was adjourned at 15.25 P.M.

Chumphol Rimsakhon-

(Mr. Chumphol Rimsakhon)

Chairman of the Meeting

-Tharakorn Junkerd-

(Mr. Tharakorn Junkerd)

Meeting Recorder

MADAME BIOSCIENCE

Enclosure 3

Profile of the director who are reappointed as the director

Name: Miss Ingfa Petvipusit

Position: Director and Chief Executive Officer

Nationality: Thai

Age: 41 years

Education:

- Bachelor of Business Administration, Major in Management, Dhurakij Pundit University

Director Training Courses with Thai Institute of Directors (IOD):

- None

Current Position:

• Listed Company:

- Director, Madame Bioscience Public Company Limited

• Non – listed Company:

- Prompt Pack Co., Ltd.
- NPP Food Incorporation Co.,Ltd.
- NPP Food Service Co., Ltd.
- Nippon Pack Trading Co., Ltd.
- Glocon International Co., Ltd.
- Pong-Sara Distribution Co., Ltd.
- Pong-Sara Manufacturing Co., Ltd.

• Current Positions in others that may cause conflict of interests to MADAME

- None

Number of MADAME Shareholding : None

Interest/No Interest in the AGM agenda : None

MADAME BIOSCIENCE

Profile of the director who are reappointed as the director

Name: Mr. Tharakorn Junkerd

Position: Director

Nationality: Thai

Age: 41 years

Education:

- Bangkok University, Master of Laws (LL.M.), Program Intellectual property law and

Director Training Courses with Thai Institute of Directors (IOD):

- Anti-Corruption: The Practical Guide (ACPG) 13/2014
- Company Secretary Program (CSP) 49/2013
- Smart Disclosure Program (SDP)
- Fundamental Practice for Corporate Secretary.
- Basic Law course and the regulation of the Listed Company.

Current Position:

• Listed Company:

- Director, Madame Bioscience Public Company Limited

• Non – listed Company:

- Director, Triton Resources Company Limited
- Director, Triton Power Company Limited
- Director, Nongree Power Plant Company Limited
- Director, Aukkrarawat Plants Renewable Energies Company Limited
- Director, Prompt Pack Co., Ltd.
- Director, NPP Food Incorporation Co.,Ltd.
- Director, NPP Food Service Co., Ltd.
- Director, Nippon Pack Trading Co., Ltd.
- Director, Glocon International Co., Ltd.
- Director, Pong-Sara Distribution Co., Ltd.
- Director, Pong-Sara Manufacturing Co., Ltd.

• Current Positions in others that may cause conflict of interests to MADAME

- None

Number of MADAME Shareholding : None

Interest/No Interest in the AGM agenda : None

MADAME BIOSCIENCE

Profile of the director who are reappointed as the director

Name: Mr. Daniel Wu

Position: Director

Nationality: Thai

Age: 78 years

Education:

- PhD of Chemical and Biomolecular Engineering- University of Delaware Chemical Engineering of National Taiwan University

Director Training Courses with Thai Institute of Directors (IOD):

- None

Current Position:

• Listed Company:

- Director, Madame Bioscience Public Company Limited

• Non – listed Company:

- Chairman China Trust Asset Management Corp Senior Executive Vice
- President China Development Financial Holding Corp
- Chairman CDIB & Partners Investment Holding Corp.
- Chairman Grand Pacific Petrochemical Corp.

• Current Positions in others that may cause conflict of interests to MADAME

- None

Number of MADAME Shareholding : None

Interest/No Interest in the AGM agenda : None

MADAME BIOSCIENCE

Enclosure 4

Details of remuneration of directors for the year 2026

According to the Board of Directors Meeting No. 2/2026 held on February 26, 2026, it was resolved to propose to the 2026 Annual General Meeting of Shareholders to consider the determination of the directors' remuneration for the year 2026 with a limit of not more than 5,500,000 baht. In this regard, the directors' remuneration in 2026 is equivalent to the directors' remuneration in 2025 with the following details:

(A) Remuneration for the Board of Director		
	Yearly remuneration (baht)	allowance fee (baht/meeting)
Chairman of the Board	250,000	30,000
Chairman of the Audit Committee	200,000	-
Director and Independent	150,000	15,000

Remark: eligible for directors who attend the meeting

(B) Remuneration for the Sub-committee (Audit Committee, Nomination and Remuneration Committee,)	
	Allowance fee (baht/meeting)
Chairman of the Committee	20,000
Director and Independent	10,000

Remark: eligible for directors who attend the meeting

(C) Other remuneration in the form of pension	
Every member of the Board of Director	Assign to the Chairman of the Board to allocate the pension from the remuneration remaining at the end of the year to each director by considering the performance and duration of work. when combined with monthly remuneration and meeting allowance, the total remuneration will not be exceeding to 5,500,000 Baht

MADAME BIOSCIENCE

Enclosure 5

Details of auditors and auditing fees for the year 2026 (Compare to the year 2025)

The Board of Directors Meeting No. 2/2026 considered appointing and fixing auditors' fee for the year 2026 as proposed by the Audit Committee. Therefore, resolved to propose to the Shareholders' Meeting for approval. It is considered appropriate for the meeting to appoint the Auditors from DIA International Audit Company Limited. to be Auditors for the fiscal year ended December 31, 2026, with the remuneration of 4,380,000 baht. The details are as follows:

Name of Company	Total of 2026 Audit fee	Comparing to 2025 Audit fee
Madame Consumer Plc.	2,100,000	3,700,000
Prompt Pack Co., Ltd.	120,000	525,000
NPP Food Incorporation Co., Ltd.	80,000	100,000
NPP Food Service Co., Ltd.	720,000	1,100,000
Fruity Dry Co., Ltd.	-	1,100,000
Nippon Pack Trading Co., Ltd.	80,000	100,000
Glocon International Co., Ltd.	120,000	210,000
Pong-Sara Distribution Co., Ltd.	500,000	600,000
Pong-Sara Manufacturing Co., Ltd.	660,000	940,000
Total	<u>4,380,000</u>	<u>8,375,000</u>

Name list of auditors of the Company and the subsidiaries

- (1) Mr. Nopparoek Pissanuwong, Certified Public Accountant Registration No. 7764 and/or
- (2) Ms. Raweevan Chuenchom, Certified Public Accountant Registration No. 7487 and/or
- (3) Mrs. Suvimol Chirtyakierne, Certified Public Accountant Registration No. 2982 and/or
- (4) Ms. Kamolmett Chirtyakierne, Certified Public Accountant No.10435

DIA International Audit Company Limited to be the auditor of the Company and subsidiaries for the year 2025

MADAME BIOSCIENCE

Enclosure 6

Proxy (Form A)

Written at.....

Date..... Month Year

I/WE.....Nationality.....Residing at.....as
a shareholder of Madame Bioscience Public Company Limited, holding the total amount of
.....shares and have the right to vote equal to votes as
follows:

Ordinary shareshares and have the right to vote equal tovotes

Hereby appoint

(A) Name.....Age.....years

Residing at No.or.

(B) Name.....Age.....years

Residing at No.or.

(C) Name.....Age.....years

Residing at No.or.

As my/our proxy to attend and vote on my/our behalf at the Annual General Meeting of the Shareholders 2026
on April 23, 2026, at 2.00 p.m., at via electronic meeting (E-AGM) or at any adjournment thereof to any other
date, time and venue.

Any actions undertaken by the proxy in the meeting shall be deemed as being done by me/us in all respects.

Signed..... Grantor

(.....)

Signed..... Proxy

(.....)

Remarks: The shareholder assigning a Proxy must authorize only one proxy to attend and vote at the meeting
and shall not allocate its number of shares to several proxies to vote separately

MADAME BIOSCIENCE

Proxy (Form B)

Written at.....

Date..... Month Year

I/WE.....Nationality.....Residing at.....as
a shareholder of Madame Bioscience Public Company Limited, holding the total amount of
.....shares and have the right to vote equal to votes as
follows:

Ordinary shareshares and have the right to vote equal tovotes

Hereby appoint

(A) Name.....Age.....years

Residing at No.or.

(B) Name.....Age.....years

Residing at No.or.

(C) Name.....Age.....years

Residing at No.or.

As my/our proxy to attend and vote on my/our behalf at Annual General Meeting of the Shareholders 2026 on
April 23, 2026, at 2.00 p.m., at via electronic meeting (E-AGM) or at any adjournment thereof to any other date,
time and venue.

I/We appoint my proxy to cast votes according to my intention in the following manner:

(A) The Proxy is entitled to cast the votes on my/our behalf at its own discretion.

(B) The Proxy must cast the votes in accordance with my/our following instruction:

Agenda item 1 To consider and certify the Minutes of the Extraordinary General Meeting of Shareholders No.

1/2026, held on January 28, 2026.

(A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.

MADAME BIOSCIENCE

(B) The Proxy must cast its vote in accordance with my/our following instruction:

Agree Disagree Abstain

Agenda item 2 To acknowledge the Company's operating result for the Year 2025.

Acknowledge

Agenda item 3 To consider and approve of the financial statements for the year ended December 31, 2025 and the report of auditor.

(A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.

(B) The Proxy must cast its vote in accordance with my/our following instruction:

Agree Disagree Abstain

Agenda item 4 To consider an approve the dividend omission of the year 2025.

(A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.

(B) The Proxy must cast its vote in accordance with my/our following instruction:

Agree Disagree Abstain

Agenda item 5 To consider and acknowledge 3 directors whose term retired by rotation and approve to re-elect those to be the Company's directors for another term and the appointment of a new director

(A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.

(B) The Proxy must cast its vote in accordance with my/our following instruction:

Appoint whole directors

Agree Disagree Abstain

Appoint individual director

5.1 Director Name: Miss Ingfa Petvipusit

Agree Disagree Abstain

5.2 Director Name: Mr.Tharakorn Junkerd

Agree Disagree Abstain

MADAME BIOSCIENCE

5.3 Director Name: Mr.Daniel Wu

Agree Disagree Abstain

Agenda item 6 To consider and approve the remuneration for Directors for the year 2026

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
- Agree Disagree Abstain

Agenda item 7 To consider and approve the appointment of the auditors and fix the audit fee for the year 2026

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
- Agree Disagree Abstain

Agenda item 8 To consider and approve the reduction of the Company's registered capital and paid-up capital by reducing the par value of the Company's shares, and to consider and approve the amendment to Clause 4 of the Company's Memorandum of Association to reflect the reduction of the Company's registered capital.

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
- Agree Disagree Abstain

Agenda item 9 To consider other matters (if any)

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
- Agree Disagree Abstain

Casting of a vote by my/our Proxy for any agenda item which is not in accordance with this Proxy Form shall be deemed an incorrect vote and is not my/our vote as the shareholder.

MADAME BIOSCIENCE

If I/We have not indicated my/our vote for any agenda item, or if the indicated vote is unclear, or if the Meeting considers or resolves any matter other than those stated above, or if there is any change or amendment to any fact, my/our proxy shall have the right to consider and cast votes on my/our behalf in all respects as it deems appropriate.

Any lawful act performed by my/our proxy in this Meeting, except in the case that my/our Proxy does not cast the votes as specified in the Proxy Form, shall be deemed as my/our own act in all respects.

Signed..... Grantor

(.....)

Signed..... Proxy

(.....)

Remarks:

- (A)The shareholder assigning a Proxy must authorize only one proxy to attend and vote at the meeting and shall not allocate its number of shares to several proxies to vote separately.
- (B)A shareholder can only assign its votes to its proxy equal to the number of the shareholder's shares as specified in this Proxy Form and cannot assign its votes partially or less than the number of shares specified herein.
- (C)In case there are agenda items other than in the agenda specified above, an additional statement can be given by the Shareholder in the Regular Continued Proxy Form B as enclosed.

MADAME BIOSCIENCE

Continued Proxy Form B

Authorization on Behalf of a Shareholder of Madame Bioscience Public Company Limited

At the Annual General Meeting of the Shareholders 2026 on April 23, 2026, at 2.00 p.m., via electronic meeting (E-AGM) or at any adjournment thereof to any other date, time, and venue.

Agenda item Re.

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
 - Agree Disagree Abstain

Agenda item Re.

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
 - Agree Disagree Abstain

Agenda item Re.

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
 - Agree Disagree Abstain

Agenda item Re.

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
 - Agree Disagree Abstain

I certify that the details in this Continued Proxy Form B are true and accurate in all respects.

Signed..... Grantor
(.....)

Signed.....Proxy
(.....)

MADAME BIOSCIENCE

Proxy (Form C)

Written at.....

Date..... Month Year

I/WE.....Nationality.....Residing at.....as
a shareholder of Madame Bioscience Public Company Limited, holding the total amount of
.....shares and have the right to vote equal to votes as
follows:

Ordinary shareshares and have the right to vote equal tovotes

Hereby appoint

(A) Name.....Age.....years

Residing at No.or.

(B) Name.....Age.....years

Residing at No.or.

(C) Name.....Age.....years

Residing at No.or.

As my/our proxy to attend and vote on my/our behalf at Annual General Meeting of the Shareholders 2026 on
April 23, 2026, at 2.00 p.m., at via electronic meeting (E-AGM) or at any adjournment thereof to any other date,
time and venue.

I/We appoint my proxy to cast votes according to my intention in the following manner:

(A) The Proxy is entitled to cast the votes on my/our behalf at its own discretion.

(B) The Proxy must cast the votes in accordance with my/our following instruction:

Agenda item 1 To consider and certify the Minutes of the Extraordinary General Meeting of Shareholders No.
1/2026, held on January 28, 2026.

(A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.

MADAME BIOSCIENCE

(B) The Proxy must cast its vote in accordance with my/our following instruction:

Agree Disagree Abstain

Agenda item 2 To acknowledge the Company's operating result for the Year 2025.

Acknowledge

Agenda item 3 To consider and approve of the financial statements for the year ended December 31, 2025 and the report of auditor.

(A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.

(B) The Proxy must cast its vote in accordance with my/our following instruction:

Agree Disagree Abstain

Agenda item 4 To consider an approve the dividend omission of the year 2025.

(A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.

(B) The Proxy must cast its vote in accordance with my/our following instruction:

Agree Disagree Abstain

Agenda item 5 To consider and acknowledge 3 directors whose term retired by rotation and approve to re-elect those to be the Company's directors for another term and the appointment of a new director

(A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.

(B) The Proxy must cast its vote in accordance with my/our following instruction:

Appoint whole directors

Agree Disagree Abstain

Appoint individual director

5.1 Director Name: Miss Ingfa Petvipusit

Agree Disagree Abstain

5.2 Director Name: Mr.Tharakorn Junkerd

Agree Disagree Abstain

MADAME BIOSCIENCE

5.3 Director Name: Mr.Daniel Wu

Agree Disagree Abstain

Agenda item 6 To consider and approve the remuneration for Directors for the year 2026

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
- Agree Disagree Abstain

Agenda item 7 To consider and approve the appointment of the auditors and fix the audit fee for the year 2026

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
- Agree Disagree Abstain

Agenda item 8 To consider and approve the reduction of the Company's registered capital and paid-up capital by reducing the par value of the Company's shares, and to consider and approve the amendment to Clause 4 of the Company's Memorandum of Association to reflect the reduction of the Company's registered capital.

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
- Agree Disagree Abstain

Agenda item 9 To consider other matters (if any)

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
- Agree Disagree Abstain

Casting of a vote by my/our Proxy for any agenda item which is not in accordance with this Proxy Form shall be deemed an incorrect vote and is not my/our vote as the shareholder.

MADAME BIOSCIENCE

If I/We have not indicated my/our vote for any agenda item, or if the indicated vote is unclear, or if the Meeting considers or resolves any matter other than those stated above, or if there is any change or amendment to any fact, my/our proxy shall have the right to consider and cast votes on my/our behalf in all respects as it deems appropriate.

Any lawful act performed by my/our proxy in this Meeting, except in the case that my/our Proxy does not cast the votes as specified in the Proxy Form, shall be deemed as my/our own act in all respects.

Signed..... Grantor

(.....)

Signed..... Proxy

(.....)

Remarks:

- (A)The shareholder assigning a Proxy must authorize only one proxy to attend and vote at the meeting and shall not allocate its number of shares to several proxies to vote separately.
- (B)A shareholder can only assign its votes to its proxy equal to the number of the shareholder's shares as specified in this Proxy Form and cannot assign its votes partially or less than the number of shares specified herein.
- (C)In case there are agenda items other than in the agenda specified above, an additional statement can be given by the Shareholder in the Regular Continued Proxy Form C as enclosed.

MADAME BIOSCIENCE

Continued Proxy Form C

Authorization on Behalf of a Shareholder of Madame Bioscience Public Company Limited

At the Annual General Meeting of the Shareholders 2026 on April 23, 2026, at 2.00 p.m., via electronic meeting (E-AGM) or at any adjournment thereof to any other date, time, and venue.

Agenda item Re.

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
 - Agree Disagree Abstain

Agenda item Re.

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
 - Agree Disagree Abstain

Agenda item Re.

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
 - Agree Disagree Abstain

Agenda item Re.

- (A) The Proxy is entitled to cast its vote on my/our behalf at its own discretion.
- (B) The Proxy must cast its vote in accordance with my/our following instruction:
 - Agree Disagree Abstain

I certify that the details in this Continued Proxy Form B are true and accurate in all respects.

Signed..... Grantor
(.....)

Signed..... Proxy
(.....)

MADAME BIOSCIENCE

Enclosure 7

Details of independent directors for proxy granting of Annual General Meeting of shareholders year 2026

Name: Mr. Anant Sirisaengtaksin

Position: Chairman of the Audit Committee and Independent Director

Nationality: Thai

Age: 74 years

Education:

- Accounting, Chulalongkorn University.
- MBA (Accounting), Eastern New Mexico University, U.S.A.
- Cert. International Tax Program, Harvard University, U.S.A.

Director Training Courses with Thai Institute of Directors (IOD):

- Director Certificate Program (DCP) No. 73/2006
- Advanced Audit Committee Program (AACP) No. 22/2016
- Capital Market Academy No. 13

Current Position:

- Listed Company: 5 Companies
 1. Chairman of the Board, Chairman of the Audit Committee and Independent Director, Global Consumer Public Company Limited.
 2. Independent Director and Chairman of the Audit Committee, Villa Kunalai Public Company Limited.
 3. Director, AIRA capital Public Company Limited
 4. Independent Director and Audit Committee, Asia Green Energy Public Company Limited.
 5. Independent Director and Audit Committee, Chiang Mai Rim Doi Public Company Limited.
- Non – listed Company:
 - None-
- Current Positions in others that may cause conflict of interests to GLOCON
 - None-

Number of GLOCON Shareholding : None

Interest/No Interest in the AGM agenda : None

MADAME BIOSCIENCE

Details of independent directors for proxy granting of Annual General Meeting of shareholders year 2026

Name/Surname: Ms. Chularat Suteethorn

Current Position: Director and Independent director, and Audit Committee.

Nationality: Thai

Age: 70 years

Education:

- Master of Development Studies (MDS), Economic Policy and Planning Institute of Social, Nederland
- Bachelor of Arts (Economics), Finance and Banking Major (Second Class Honors), Kasetsart University

Director Training Courses with Thai Institute of Directors (IOD):

- Director Accreditation Program (DAP) Class 40/2005
- Director Certification Program (DCP) Class 72/2006
- Finance for Non - Finance Director (FND) Class 28/2006
- Financial Statement for Director (FSD) Class 10/2010
- Audit Committee Program (ACP) Class 39/2012
- Risk Management Program for Corporate Leaders (RCL) Class 21/2020
- Boards that Make a Difference (BMD) Class 10/2020
- The Cullinan, The Making of the Digital Board Class 1/2022

Current Position:

- Listed Company: 3 Companies
 - Independent Director, Audit Committee, DTC Enterprise PCL
 - Independent Director, AEON Thana Sinsap (Thailand) PCL.
 - Independent Director Chairman of Audit Committee and Risk Management Committee, Seafco PCL.
 - Director Country Group Holdings PCL.
- Non – listed Company:
 - Advisor, Boolim Entertainment Company Limited
 - Chairman of the Executive Committee, Cloud Communication Company Limited
 - Chairman of the Executive Committee, Wealth Factory Krabi Company Limited
- Current Positions in others that may cause conflict of interests to GLOCON
 - None

Number of MADAME Shareholding : None

Interest/No Interest in the AGM agenda : None

Articles of Regulation Rules for shareholder meeting

Chapter 5: Shareholder meeting

No.30 – The Board of Directors shall convene a shareholders’ meeting as an annual ordinary meeting within 4 (four) months as from the last date of the Company’s accounting period.

Shareholders’ meetings other than those mentioned in Paragraph 1 shall be called extraordinary meetings. The Board of Directors may summon a shareholders’ meeting as an extraordinary meeting at any time as it may deem expedient.

One or several shareholder(s) representing shares equal to not less than 10% of the total number of shares issued or subscribed shall execute a letter requesting the Board of Directors to summon a shareholders’ meeting as an extraordinary meeting at any time but it shall be clearly specified with matters and reasons for summoning the meeting in such letter. In such case, the Board of Directors shall convene a shareholders’ meeting within 45 (forty-five) days as from the date of receiving such letter from shareholder(s).

In case, the Board of Directors failed to convene a meeting within the prescribed period of time under Paragraph 3, all shareholders subscribing or other shareholders jointly representing the number of shares as required may summon a meeting within 45 (forty-five) days as from the due date thereof under Paragraph 3. In such case, such meeting shall be regarded as the Shareholders’ Meeting summoned by the Board of Directors; whereas, the Company shall be responsible for necessary expenses incurred from the convening of such meeting and to provide reasonable facilitation thereto.

In case, it appeared that in any shareholders’ meeting which was summoned by shareholder(s) under Paragraph 4, the number of shareholders attending the Meeting which could not constitute a quorum as prescribed in Clause 35 hereof, shareholders under Paragraph 4 shall assume their joint responsibilities for reimbursement of expenses incurred from convening such meeting to the Company.

No.31 – Regarding the summoning of the Meeting, the Board of Directors shall provide invitation for the meeting specified with the venue, date, time, agenda and matters to be proposed to the Meeting, together with proper details, and clearly specified as matters to be proposed to the Meeting for acknowledgment, approval or consideration, as the case may be, including opinions of the Board of Directors on such matters, and shall submit it to shareholders and the Registrar for acknowledgment for at least 7 days prior to the date of the Meeting, and shall publish the notice of summoning of

MADAME BIOSCIENCE

the Meeting in newspapers for 3 consecutive days and for at least 3 days prior to the date of the Meeting. The Shareholders' Meeting shall possibly hold in another area from where the head office or a branch office of the company is located or nearby province.

No.32 – In a shareholders' meeting, shareholders shall be entitled to attend and cast their votes in a shareholders' meeting; however, they may appoint their proxies to attend and cast their votes in such meeting. In case of proxy, such proxy notice shall be submitted to the Chairman of the Board of Directors or the person fixed by the Chairman of the Board of Directors at the venue of the Meeting before their proxies shall attend such meeting.

No.33 – In a shareholders' meeting, at least 25 shareholders and their proxies (if any) shall attend the meeting or not less than half of the total number of shareholders and representing not less than one-third of the total number of the issued shares to constitute a quorum.

In case, it appeared that, in any shareholders' meeting, such appointment time of the meeting has been elapsed for an hour, and the number of shareholders attending the meeting did not constitute a quorum as prescribed, in case, such shareholders' meeting was summoned upon the shareholder's request, then, such meeting shall be cancelled. In case, such shareholders' meeting was summoned not upon the shareholder's request, then, such meeting shall be reconvened and a notice of the meeting shall be sent to shareholders for not less than 7 (seven) days before the date of the meeting; provided that in the latter meeting, no quorum shall be required.

No.34 – In every shareholders' meeting, the Chairman of the Board of Directors shall be the Chairman of the meeting. If the Chairman is not present at the meeting or unable to perform the duties for any reason, the Vice Chairman shall be the Chairman of the meeting instead. If the Vice Chairman is not present at the meeting or is unable to perform his duties as well, the shareholders attending the meeting shall elect one shareholder to be the Chairman of that particular meeting.

No.35 – In voting, one share shall represent one vote, and the resolution of the shareholders' meeting shall consist of the following votes:

(1) In normal cases, a resolution thereof shall be passed by the majority votes of shareholders attending and casting their votes in the meeting. In case of a tie, the Chairman of the Meeting shall have one additional and casting vote.

(2) In the following cases, a resolution thereof shall be passed by at least three-fourth of the total number of votes of shareholders attending and having rights to cast votes in the meeting:

(a) Divestiture or transfer of the whole or material part of the Company's business to a third party;

MADAME BIOSCIENCE

(b) Acquisition or acceptance of transfer of business of other companies or private companies to be owned by the Company;

(c) Execution, amendment or cancellation of contracts relating to the leasing out of the whole or material part of the Company's business,

Assignment of a third party to manage the Company's business, or amalgamation of business with a third party with an objective of sharing of profits and losses;

(d) Amendment of the Memorandum of Regulation or Articles of Association;

(e) Increasing or decreasing the capital of the Company or issuing debentures;

(f) Merger or dissolution of the Company.

No.36 – The following business at the Annual General Meeting shall be done:

(1) The Board of Directors shall present the annual operating results and jointly propose advice on business operation in the future;

(2) Consideration and approval of balance sheets and the profit and loss accounts of the previous year;

(3) Consideration and allocation of dividends, profits, reserves (if any), including directors' remunerations;

(4) Election of new directors in place of the retiring directors;

(5) The meeting shall consider the determination of directors' remuneration.

(6) The meeting shall consider the appointment of the auditor and determine the amount of audit fees.

(7) Consideration of other businesses that the Board of Directors deemed expedient to ask for a resolution in the general meeting, including businesses required by laws to receive a resolution in the general meeting

Chapter 7 Capital Increase and Capital Decrease

No. 46 – The Company may increase its capital from the registered by issuing new shares to increase its capital in accordance with the resolution of the shareholders' meeting with a vote of not less than three-fourths of the total number of votes of shareholders attending the meeting and having right to vote. Newly issued shares in the capital increase may be offered for sale in whole or in part. and will be offered to the shareholders in proportion to the shareholder or will be offered to the public or other persons, whether in whole or in part, in accordance with the resolution of the shareholders' meeting.

MADAME BIOSCIENCE

No. 47 – The Company will reduce its capital from the registered capital by reducing the value of each share to a lower or reduce the number of shares or cut off registered shares that cannot be sold or that have not been sold.

Rules for attending the shareholders' meeting via electronic media (E-AGM)

Shareholders or proxies who wish to attend the meeting must submit documents proving their identity as specified to the Company within **April 22, 2026**. The Company shall verify the list of shareholders according to the closing information of the shareholders' register book, who have the right to attend the meeting wholly and correctly. After that, the electronic conferencing service provider will send a Link to attend the meeting and the user manual to the email you have sent to inform the Company. The Link will be sent 2 days in advance of the meeting date.

Requesting to attend the meeting via electronic media

Shareholders wishing to attend the meeting via electronic media must notify their intention to attend the meeting in two ways as follows:

1. Submit your request to attend the meeting by sending information via Email or postal mail.
2. Submit your request to attend the meeting by sending information via the website or QR Code.

If shareholders wish to notify their intention to attend the meeting via electronic media (E-AGM) by sending information via Email or postal:

1. Please fill in the document requesting to attend the meeting via electronic media (E-AGM) (Enclosure10) by specifying your Email and your mobile phone number clearly for registering for the meeting.
2. Attach a copy of proof of identity to confirm the right to attend the E-AGM meeting.
 - 2.1 Shareholders who are natural persons:
 - If a shareholder wishes to attend the meeting in person via E-Meeting:
 - Attach a copy of a valid government-issued identification document such as an ID card, government ID card, driver's license, or passport. In case of name-surname changes, shareholders are requested to attach supporting evidence.
 - If a shareholder appoints another person to attend the meeting on his/her behalf via E-Meeting:
 - The Proxy (attached with the invitation letter) is filled in all information signed by the proxy grantor and the proxy correctly and entirely together with duty stamp affixed;

MADAME BIOSCIENCE

- A copy of the proxy grantor's identity document, such as an ID card, a government official ID card, passport (In the case of foreigners) that has not expired and signed certifying the true copy of the proxy.
- A copy of the proxy's identity document, such as an ID card, a government official an ID card, passport (In the case of foreigners) that have not expired and signed certifying the true copy of the proxy.

2.2 Shareholders who are juristic persons:

- If the person authorized to sign on behalf of the juristic person (director) wishes to attend the meeting in person via electronic media (E-Meeting)
 - A copy of the shareholder's juristic person registration certificate issued no later than one year before the date of the shareholders' meeting, which is duly certified by the juristic person representative (director) authorized to sign on behalf of the juristic person.
 - A copy of the identity document of the representative of the juristic person (director), such as an ID card, a government official ID card, passport (In the case of foreigners) that has not expired and signed to certify the true copy.
- If the proxy is assigned to attend the meeting instead via electronic media (E-Meeting)
 - The Proxy (attached with the invitation letter) is filled in all information signed by the proxy grantor and the proxy correctly and entirely together with duty stamp affixed;
 - A copy of the shareholder's juristic person registration certificate issued no later than one year before the date of the shareholders' meeting, which is duly certified by the juristic person representative (director) authorized to sign on behalf of the juristic person.
 - A copy of the identity document of the representative of the juristic person (director), such as an ID card, a government official ID card, passport (In the case of foreigners) that has not expired and signed to certify the true copy.
 - Copy of the identity document of the proxy as in the case of natural persons as mentioned above.


Suppose the documents or evidence mentioned above are not Thai or English versions. In that case, the shareholders must present an English translation of the document signed to certify the translation by the shareholder or by an authorized signatory to bind that juristic person (in the case of a juristic person).

MADAME BIOSCIENCE

3. Submit the documents requesting to attend the meeting via electronic media (item 1) and proof of identity together with supporting documents (item 2) by sending to the Company within the date April 22, 2026.
- Email channel : glocon@ojconsultinggroup.com
 - Postal channels : OJ International Company Limited., 5/6 Tessaban Rangsarit Nuea Road, Lat Yao, Chatuchak, Bangkok 10900

If a shareholder wishes to submit a request to attend the meeting via electronic media (E-AGM) via the website or QR Code

1. Request to attend the meeting via Web Browser: Chrome by going to

Scan QR Code	Go to Link
	https://madame.thekoble.com/agm/emeeting/index/1

2. Fill in the information of shareholders:
 1. Securities holder account number;
 2. Name (do not include a title) If the shareholder is a juristic person, do not fill in this field;
 3. Last Name (In case the shareholder is a juristic person, enter the name of the juristic person in the last name field);
 4. ID card number;
 5. Attach the file of the company certificate (In the case of a shareholder who is a juristic person);
 6. Choose to accept the terms and consent to access to personal information;
 7. Press "Confirm"
3. Check the name of the shareholder and the number of shares. If correct, please fill in shareholder information.
 1. Name - Surname (English);
 2. Email to receive a link to attend the meeting;

MADAME BIOSCIENCE

3. Mobile phone number;
4. Select the attendance type:
 - i. Attend the meeting in person via E-AGM;
 - ii. Authorize the natural persons to attend the meeting via E-AGM;
 - iii. Assign a proxy to an independent director;
5. Press "Next"

In the case of appointing the natural person to attend the meeting via E-AGM:

Prepared shareholders' identification documents

1. Attach a copy of the shareholder's identity document;
2. Attach a copy of other identity documents;
3. Press "Next";
4. Save the proxy's information and attach supporting documents:
 - a. Name-surname of the proxy (Thai language);
 - b. Name-surname of the proxy (English);
 - c. Attach a copy of the proxy's identity document;
 - d. Attach the proxy form with complete information and signature;
5. Press "Next";
6. The system will display a message "Information received successfully," check the name, surname and number of shares again;
7. Close window to finish;

In the case of appointing a proxy to an independent director:

1. Attach a copy of the shareholder's identity document (Like in the case of shareholders attending the meeting in person);
2. Attach the completed and signed proxy form;
3. Press "Next";
4. The system will display a message "Information received successfully," check the name, surname and number of shares again;
5. Close window to finish;

MADAME BIOSCIENCE

Remark: The system for receiving the request to attend the meeting will be open for operation from April 22, 2026 or until the meeting is completed. (The system does not accept information on Saturdays, Sundays, and public holidays.)

Suppose the documents or evidence mentioned above are not Thai or English versions. In that case, the shareholders must present an English translation of the document signed to certify the translation by the shareholder or by an authorized signatory to bind that juristic person (in the case of a juristic person).

Electronic Meeting Attendance (E-AGM):

1. Once the shareholders or proxies wish to attend the meeting and have been fully verified, you will receive an Email from the meeting organizer, a link for attending the meeting, and a system's user manual two days before the meeting date. Please study the manual on how to use the E-AGM meeting system in detail. If you haven't received the Email within the April 22, 2026, please get in touch with the Company immediately.
2. Please prepare the following information for logging in the meeting
Self-Attending: Shareholder Account Number (10 digits Number) and ID Card.
Proxy: Proxy ID Card and Proxy's Mobile Number.
3. Meeting attendance and voting via electronic media can be used with computers/notebooks/tablets and mobile phones via Web Browser: Chrome with 4G internet speed or home internet basic.

MADAME BIOSCIENCE

Remark: In case of meeting via tablet and mobile phone, Zoom Cloud Meeting program must be installed before attending the meeting, which can be downloaded as follows:

IOS system	Android system
	
https://apps.apple.com/th/app/zoom-cloud-meetings/id546505307	https://play.google.com/store/apps/details?id=us.zoom.videomeetings

4. The system will open for meetings 60 minutes before the start of the meeting. However, the live broadcast will only start at the time of the meeting.
5. To log in, attendees must use the information of the shareholder registration number and the shareholder's ID card number.
6. Voting through the E-Voting system, you will be able to vote for each agenda only by voting for agreeing, disagreeing, or abstaining. In case of not voting in any agenda, the system will be deemed to vote as agree immediately (using the vote-counting method by pouring votes towards agreeing).
7. If attendees have any problems or problems in using the E-AGM system, you can contact OJ International Co., Ltd. at the phone number specified in the Email that sends you the system's user manual.

***** This E-AGM meeting will be an electronic meeting only and will not be held in a conventional meeting venue; therefore, shareholders are requested not to come to the Company. *****

If a shareholder wishes to appoint an independent director as a proxy:

Suppose any shareholders cannot attend the E-AGM meeting in person or cannot appoint other proxies to attend the E-AGM meeting and wish to appoint an independent director as a proxy. In this regard, they can

MADAME BIOSCIENCE

send a proxy form (Enclosure 6) specifying the proxy as one of the independent directors as specified by the Company along with supporting documents to the Company by the date within the date **April 22, 2026** via the following channels:

- By Email: glocon@ojconsultinggroup.com
- By mail: OJ International Company Limited., 5/6 Tessaban Rangsarit Nuea Road, Lat Yao, Chatuchak, Bangkok 10900

Remark: If the shareholders specify their votes in each agenda, the independent directors will cast their votes as specified in the proxy form. In which the voting in each agenda, shareholders have the right to vote in agreeing, disagreeing, or abstaining only and cannot divide a partial vote (unless it is a Custodian vote).

In the case of a shareholder who is a foreign investor and appoints a custodian in Thailand to be a stock depository and keeper:

Please submit the following information:

1. The Proxy Form C (attached with the invitation letter) is filled in all information signed by the proxy grantor and the proxy correctly and entirely together with a 20-baht duty stamp affixed;
2. Custodian juristic person registration certificate (Custodian) with a signature certifying true copy by the authorized signatory on behalf of the juristic person of the Custodian or the attorney with the corporate seal (if any).
3. A power of attorney from the shareholders for the Custodian to be authorized to sign the proxy form;
4. A letter confirming that the person signing the proxy form is authorized to operate a custodian business;
5. Copy of ID card, or a copy of government official ID card, or copy of passport (In the case of foreigners) of the proxy with certified the true copy;
6. Submit information via the following channels:

By Email : glocon@ojconsultinggroup.com

By mail: OJ International Company Limited., 5/6 Tessaban Rangsarit Nuea Road, Lat Yao, Chatuchak, Bangkok 10900

MADAME BIOSCIENCE

Submitting advice or questions related to business, industry, Company performance, or related to any agenda which will be considered at the E-AGM meeting:

If shareholders wish to submit suggestions or questions, they can be done in two ways as follows:

1. Send advice or questions **in advance** to the Company before the meeting date through the following channels:
 - By Email : legal@glocon.co.th
 - Telephone: 02-5535000 # 333
 - By mail: Company Secretary of Global Consumer Public Company Limited
No.60 Soi Praditmanutham19, Praditmanutham Road, Ladprao, Bangkok 10230
2. Submit advice or questions during the meeting to those attending the E-AGM meeting. The attendee must specify his/her first and last name and state whether his/her is a shareholder attending the meeting himself/herself or a proxy. Before every suggestion or question is submitted, the Company has opened channels for sending advice and questions during the meeting as follows:
 - Q&A channel for text messages;
 - An audio chat channel where attendees press the raising hand button and turn on the microphone on their device after the operator sends you an invitation to chat. Please turn off the microphone after the conversation is finished every time (For more details, please refer to the user manual sent to the attendees' Emails).

In this regard, if shareholders have questions about the meeting, they can contact the following staff:

1. Regarding submitting documents confirming identity to attend the shareholders' meeting via E-Meeting, please contact the Company Secretary for further information via the Company's contact channels as detailed above.
2. Regarding the process of attending the meeting and voting via E-Meeting, in the case of correct and complete identity verification, please contact OJ International Co., Ltd. at the phone number specified in the Email that sends you the system's user manual.

MADAME BIOSCIENCE

Enclosure 10

Acceptance for the invitation of online meeting of Madame Bioscience Public Company Limited

.Date.....Month.....Year.....

(1) I/We..... Nationality.....Identification Card/Passport
number.....Residing at No..... Road.....

Subdistrict.....District.....Province.....Postal Code.....

(2) Being a shareholder of Madame Bioscience Public Company Limited.

Holding the total amount.....share.

I would like to participate in the E-AGM for Annual General Meeting 2026

(Self-Attending) Mobile Number.....Please fil in the blank.

Proxy to.....attend the meeting.

Proxy's Mobile Number.....Please fil in the blank.

(3) Please send the Link to join the meeting by below email.

E-Mail..... please fil in the blank.

(4) Please submit the required document per an attachment 10. by April 22, 2026.

(5) Once you have verified, the company will send the Link to join the meeting via email.


(6) Please prepare your Account Number and your Identification Card Number for log in the meeting.

Signed..... Shareholder

(.....)

MADAME BIOSCIENCE

E-AGM Flowchart



Procedure for submitting questions about the shareholders' meeting

The Board of Directors deems it appropriate to allow shareholders to express their opinions, and or send questions about the shareholders' meeting to the Board of Directors in advance of the Meeting date. Shareholders can submit their opinions and/or questions to the Company via the following channels;

1. Shareholders who have opinions and/or questions, please provide your information with details as follows;
 - Name, address, telephone number, fax number and e-mail (if any) that the company can contact
 - Comments and/or questions you want to ask along with documents and attached information (if any)

2. Channels to submit comments and/or questions

- Email : legal@glocon.co.th
- Line ID : ir_glocon



3. Open-time for opinion and/or question

The Company invites shareholders to submit their opinions and/or questions about the Shareholders' Meeting from now until April 22, 2026

4. The Company Secretary will collect opinions and/or questions and send it to the Chairman of the Board of Directors or relevant executive directors to consider and answer such questions to the shareholders on the next Shareholder Meeting.

